<DOC>
	<DOCNO>NCT00988325</DOCNO>
	<brief_summary>This study ass pharmacokinetics/pharmacodynamics safety oseltamivir [ Tamiflu ] therapy infant less 1 year age influenza diagnose 96 hour prior first dose . Patients age 3-12 month receive 3 mg/kg , 1-3 month receive 2.5 mg/kg , birth 1 month receive 2 mg/kg twice day total 10 dos . Patients positive influenza virus Day 6 eligible receive continue study treatment additional 10 dos ( 5 day ) . The anticipated time study treatment 4 week , target sample size 65-85 male female infant .</brief_summary>
	<brief_title>A Pharmacokinetic/Pharmacodynamic ( PK/PD ) Safety Evaluation Oseltamivir Tamiflu Treatment Infants 0 &lt; 12 Months Age With Confirmed Flu Infection</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>infant &lt; /=12 month age laboratory confirm diagnosis influenza within 96 hour prior first dose influenza symptom &lt; /=96 hour prior first dose preterm infant le 40 week ( correct gestational age ) weight less 5th percentile age ( correct gestational age ) concurrent gastrointestinal condition preclude enteric absorption drug bronchopulmonary dysplasia/chronic lung disease assist ventilation time enrollment active uncontrolled respiratory , cardiac , hepatic , CNS renal disease baseline symptomatic inborn error metabolism</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>